These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: The incidence of antibody formation to OKT3 consequent to its use in organ transplantation.
    Author: Carey G, Lisi PJ, Schroeder TJ.
    Journal: Transplantation; 1995 Jul 27; 60(2):151-8. PubMed ID: 7624957.
    Abstract:
    Enzyme-linked immunosorbent assays were performed on 12,133 serum samples to determine the incidence of anti-OKT3 antibody formation among transplant recipients who had received OKT3 for rejection treatment or prophylaxis. High anti-OKT3 antibody titers (> or = 1:1000) were detected in 5.8% of samples drawn 2 to 8 weeks following initiation of OKT3 therapy. The frequency of high titers differed by organ (6.9%, 2.7%, and 5.3% for kidney, heart, and liver, respectively; P < 0.001) and by sampling times (P < 0.001). The highest frequency of positive titers was obtained in samples obtained between 2 and 4 weeks following the initiation of OKT3. For all transplant recipients and for kidney recipients alone, multivariate logistic regression showed that the risk of high anti-OKT3 titers varied significantly at 2 to 4 weeks and at 4 to 6 weeks (but not at 6 to 8 weeks) with age (the youngest patients had the highest incidence, with a steady decline after age 30; P < 0.05), course of therapy (lowest frequencies followed a first course of OKT3; P < 0.001), and transplant number (lowest frequencies followed a first transplant; P < 0.01). Analyses of a set of patients on whom immunosuppressive regimen information was available indicated that prophylactic or maintenance treatment with CsA was associated with a significantly lower frequency of high-titer anti-OKT3 antibodies than was therapy without CsA (P < 0.001). In conclusion, this series provides confirming evidence that high-titer anti-OKT3 antibodies, which are of concern whenever retreatment with OKT3 is contemplated, occur in a low percentage of patients and are associated with such factors as age, previous transplantation or courses of therapy with OKT3, and treatment with CsA.
    [Abstract] [Full Text] [Related] [New Search]